At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
Akt Inhibitor MK2206 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
In Brief
A Phase 2 clinical trial evaluating Akt Inhibitor MK2206 and Laboratory Biomarker Analysis for Endometrial Adenocarcinoma and 4 related conditions. Completed, enrolled 37 participants across 7 sites.
Detailed Summary
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with recurrent or advanced endometrial cancer. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedMar 2011
Primary CompletionSep 2015
TodayJul 2026
First PostedMar 3, 2011
Enrollment StartMar 1, 2011
Primary CompletionSep 18, 2015
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 15.3 years ago
Interventions
Akt Inhibitor MK2206drug
Given PO
Laboratory Biomarker Analysisother
Correlative studies